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 Pathogenesis of Thrombotic Microangiopathy:
Insights from Animal Models 
 Anna Richards a    David Kavanagh b 
 a  MRC Centre for Inflammation Research, Queens Medical Research Institute, Edinburgh, and  b  Department of 
Nephrology, The Institute of Human Genetics, Newcastle University,  Newcastle upon Tyne , UK 
 Thrombotic Microangiopathies 
 Thrombotic microangiopathies (TMAs) are a group of 
conditions characterised by microvascular thrombosis 
leading to thrombocytopenia, haemolytic anaemia and 
red cell fragmentation  [1] . The clinical manifestation of 
TMA is determined by the specificity of the process for 
different endothelial cell beds. This led to the historical 
differentiation between haemolytic uraemic syndrome 
(HUS)  [2] and thrombotic thrombocytopenic purpura 
(TTP)  [3] . For example, in TTP there is predominantly 
brain microvascular endothelial cell injury, resulting in 
neurological disturbance, while in HUS there is primar-
ily glomerular endothelial cell injury resulting in acute 
renal impairment.
 Many different aetiological predisposing factors for 
the development of TMA have been described. The post-
diarrhoeal form of HUS (D+ HUS) is most commonly 
precipitated by Shiga-toxin (Stx)-producing  Escherichia 
coli.  Other precipitating factors for TMA include:  Strep-
tococcus pneumoniae infection, pregnancy, drugs (beva-
cizumab, mitomycin) and malignancy. However, TMAs 
only manifest in a small proportion of patients exposed 
to these environmental stimuli, suggesting additional ge-
netic predispositions. Recent advances in molecular biol-
ogy have begun to identify these factors. TTP has been 
shown to be predisposed to by a genetic deficiency of
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 Abstract 
 Animal models are important experimental tools for inves-
tigating the molecular mechanisms, environmental and 
 genetic susceptibilities underlying the development of 
thrombotic microangiopathies. Large mammal, small ani-
mal models, knockout, transgenic and conditional knockout 
mouse models are available to investigate haemolytic urae-
mic syndrome, thrombotic thrombocytopenic purpura and 
vascular endothelial growth factor-associated thrombotic 
microangiopathy. These models have shown that it is pos-
sible to model the human conditions. However, differences 
in human and rodent physiology mean that caution is re-
quired when interpreting the findings. These models offer 
realistic prospects for identifying and testing novel thera-
peutic strategies in a range of thrombotic microangiopa-
thies prior to human trials.  Copyright © 2009 S. Karger AG, Basel 
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ADAMTS13 (the rare Upshaw-Schulman syndrome) or 
more commonly from production of inhibitory anti-
 ADAMTS13 antibodies  [3] . By contrast, the non-diar-
rhoeal form of HUS, atypical HUS (aHUS), is predis-
posed to by mutations in, or antibodies against, comple-
ment regulatory proteins  [2] .
 Discovery of these genetic predispositions has allowed 
generation of specific knockout and transgenic mouse 
models to add to existing Stx models of TMA. These are 
now yielding significant advances in the understanding 
of disease pathogenesis and provide models to screen 
 potential therapeutic agents. The strengths and possible 
limitations of this experimental approach are reviewed 
here.
 Animal Models of Thrombotic Microangiopathies 
 ( tables 1, 2 ) 
 Initial attempts to generate animal models of throm-
botic microangiopathies focused on oral administration 
of Stx-producing  E. coli or parenteral administration of 
Stx.
 Non-Rodent Models of D+ HUS 
 Greyhound – Shiga Toxin 
 ‘Alabama rot’ is a naturally occurring model of D+ 
HUS which was first recognised at a greyhound race track 
in Alabama. Racing greyhounds are fed raw meat from 
rendering plants which commonly contains pathogenic 
Table 1. Toxin models of TMAs
Model Trigger Pathology Ref.
Shiga toxins
Mouse oral E. coli O157:H7; Sm renal cortical tubular necrosis Wadolkoski et al. (1990)
Mouse IV/IP Stx1, Stx2 necrosis of tubular cells Tesh et al. (1993)
Mouse IG E. coli O157:H7 tubular necrosis Karpman et al. (1997)
Mouse SQ IP LPS + IV Stx2 tubular necrosis Palermo et al. (1999, 2000)
Mouse IV Stx2 widespread mesangial hypercellularity, cresent formation Dran et al. (2002)
Mouse IV Stx2 + L-NAME widespread mesangial hypercellularity, cresent formation,
glomerular thrombosis, tubular necrosis
Dran et al. (2002)
Mouse IV Stx1, Stx2 necrosis of tubular cells Rutjes et al. (2002)
Mouse SQ IP LPS + Stx2 mild glomerular endothelial damage Ikeda et al. (2004)
Mouse IP LPS + Stx2 thrombocytopenia, haemolytic anaemia, renal failure, fibrin thrombi Keepers et al. (2006, 2007)
Mouse IP Stx2 haemolysis, renal failure, glomerular fibrin deposition Sauter et al. (2008)
Mouse oral enterohemorrhagic E. coli
germ-free mice
renal tubular necrosis, glomerular capillary RBC sludging and 
occasional fibrin thrombi
Eaton et al. (2008)
Rat IV Stx2 acute tubular injury Zhao et al. (2002)
Rat IP E. coli Stx2 supernatant tubular + glomerular necrosis, glomerular fibrin thrombi Zotta et al. (2008)
Ferret oral E. coli O157:H7; Sm some develop glomerular fibrin thrombi, occasionally thrombocytopenia Woods et al. (2002)
Dutch belted rabbits oral E. coli O153 glomerular fibrin thrombi + tubular necrosis Garcia et al. (2002)
Gnotobiotic piglets oral E. coli O157:H7 glomerular TMA, no renal failure, no thrombocytopenia Gunzer et al. (2002)
Greyhounds oral E. coli O157:H7 glomerular TMA Hertzke et al. (1995)
Baboon IV Stx1, Stx2 renal TMA
thrombocytopenia, MAHA, renal failure
Taylor et al. (1999)
Siegler et al. (2003)
Endothelial toxins
Mouse IV/IP ricin 8 LPS thrombocytopenia, haemolytic anaemia, renal failure, glomerular
fibrin thrombi
Taylor et al. (1999)
Mouse transplantation of hybridoma 
clone (anti-platelet Ab)
thrombocytopenia, microthrombi in small vessels of lung Hashimoto et al. (2000)
Mouse SQ RAP Con A + anti-Con A Ab glomerular + peritubular microvascular thrombosis + tubular necrosis Hohenstein et al. (2008)
Rat mitomycin perfusion of kidney renal TMA Cattell et al. (1985)
Rat RAP anti-GEC Ab renal TMA Nangaku et al. (1997)
Rat IV anti-EC Ab thrombocytopenia, tubular injury, occasional glomerular intracapillary 
thrombi
Ren et al. (2002)
Other
Dog/pig botrocetin platelet microthrombi in lungs and spleen Sanders et al. (1995)
Rats botrocetin platelet microthrombi in lungs and spleen Sanders et al. (1988)
Sm = Streptomycin pre-treated; IV = intravenous; IP = intraperitoneal; LPS = lipopolysaccharide; SQ = sequential administration; IG = intragastric;
GEC = glomerular endothelial cell; EC = endothelial cell; RAP = renal artery perfusion; RBC = red blood cell; TMA = thrombotic microangiopathy.
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 E. coli . These dogs develop bloody diarrhoea, skin ulcers 
and renal failure. The renal pathology is of an extensive 
glomerular TMA. Preliminary experiments using this 
model demonstrated that treatment with Lepirudin, a re-
combinant hirudin anticoagulant that binds thrombin, 
prevented the lethal effects of Stx2.
 Baboon – Shiga Toxin 
 Siegler et al. [4] developed a baboon model of Stx-me-
diated HUS. Animals given IV Stx1 or Stx2 developed 
progressive thrombocytopenia, haemolytic anaemia and 
renal failure. Glomerular thrombotic microangiopathy 
was found at necropsy. This model demonstrated that 
Stx2 is a more potent initiator of D+ HUS than Stx1.
 Rodent Models of D+ HUS 
 Small Animal Models – Shiga Toxin 
 Thus, canine and baboon models of HUS mimic the 
human disease; however, they are impractical and costly. 
Small animal models of Stx HUS have proved a poor ho-
mologue of human disease, with most developing tubular 
damage without glomerular thrombosis ( table 1 ). This is 
felt to relate to interspecies variability in the expression 
of the Stx receptor, Gb3, which is absent in mouse glom-
eruli. However, murine renal tubules do express Gb3, 
which provides an explanation for the pattern of disease 
in mice exposed to Stx.
 Keepers et al.  [5] recently demonstrated that intraper-
itoneal co-injection of purified Stx2 plus lipopolysaccha-
ride in mice resulted in the classical triad of thrombocy-
topenia, haemolytic anaemia and renal failure seen in 
 human HUS. However, it has been suggested that this 
glomerular pathology could follow primary tubular dam-
age  [6] .
 Endothelial Cell Toxin Model of TMA 
 Mitomycin C, an alkylating chemotherapy agent, is 
thought to cause renal thrombotic microangiopathy by a 
direct toxic effect on endothelium. When mitomycin was 
perfused into kidneys of rats, a pathological picture re-
sembling HUS resulted, with fibrin deposition and endo-
thelial cell proliferation.
 Antibody-Mediated Models of TMA 
 Nangaku et al.  [7] generated a rat model of TMA that 
histologically and clinically resembles HUS by selective 
unilateral renal artery perfusion of antibodies against 
glomerular endothelial cells. This injury was prevented 
by using rats that had undergone complement depletion 
using cobra venom factor or were genetically C6-defi-
cient, suggesting a role for membrane attack complex for-
mation in the pathogenesis. Additional studies using this 
model also suggested a role for C5b-9-mediated endothe-
lial cell apoptosis and showed protective effects of VEGF. 
Table 2. Genetically modified models of TMAs
Model Trigger Pathology Ref.
Complement k/o
Norwegian Yorkshire pig spontaneous MPGN Hegasy et al. (2002)
Mouse CFH–/– spontaneous MPGN Pickering et al. (2002)
Mouse CFH+/– IP Stx2 + LPS no TMA, no difference in tubular injury
compared to controls
Paixao-Cavalcante et al. (2009)
Mouse CFH–/–16–20 spontaneous aHUS Pickering et al. (2007)
Mouse C5–/– CFH–/–16–20 spontaneous no aHUS Goicoechea de Jorge et al. (2008)
Mouse CFI–/– spontaneous mesangial C3 deposits with nodular expansion Rose et al. (2008)
ADAMTS 13 k/o
Mouse ADAMTS 13–/– (129/Sv) N/A none Banno et al. (2006)
Mouse ADAMTS 13–/– (C57BL/6;129x1/Sv) N/A none Motto et al. (2005)
Mouse ADAMTS 13–/– (CASA/Rk) spontaneous TTP like lesions (in some) Motto et al. (2005)
Mouse ADAMTS 13–/– (CASA/Rk) IV Shiga toxin TTP like lesions (in most) Motto et al. (2005)
VEGF k/o
Mouse VEGFA–/– spontaneous major vascular defects Carmeliet et al. (1996)
Mouse podocyte VEGFA–/– spontaneous perinatal death, grossly abnormal glomeruli Eremina et al. (2003)
Mouse conditional podocyte VEGFA–/– spontaneous TMA Eremina et al. (2008)
Renin angiotensin TG
R+/A+ high salt diet/L-NAME glomerular fibrin thrombi, mesangiolysis Sethi et al. (2006)
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A further rat model of TMA with renal disease was de-
veloped by Ren et al. [ 8 ], using a complement-fixing an-
tibody to endothelial cells. EC injury was prevented by 
complement depletion and worsened by blockade of Crry. 
Hashimoto et al. [ 9 ] generated a hybridoma clone in lu-
pus-prone mice (MRL/ lpr ) which, when transplanted 
into syngeneic non-autoimmune mice, caused microvas-
cular intraluminal platelet aggregation, thrombocytope-
nia and anaemia. This pathogenic autoantibody (anti-
gp70) specifically precipitated a platelet protein with an 
approximate relative molecular mass of 40 kDa. These 
studies replicate human studies that have demonstrated 
the presence in patients’ plasma of IgG antibodies reac-
tive with a platelet and/or endothelial cell antigen, espe-
cially CD36 in HUS and TTP.
 Specific Pathophysiological Models 
 Complement Mouse Models of aHUS 
 Mutations in the complement regulatory proteins have 
been shown to predispose to aHUS  [2] . This has provided 
alternative targets for the generation of mouse models of 
aHUS. Mutations in the complement regulator factor H 
have   been   linked   to   two   different   human   renal   diseas-
es: membranoproliferative glomerulonephritis (MPGN) 
and aHUS. Although both are associated with complete 
factor H deficiency, aHUS is more commonly associated 
with heterozygous mutations in the C-terminal of  CFH 
resulting in normal plasma levels of CFH.
 To investigate the role of factor H in disease, Pickering 
et al. [10] developed a mouse  CFH knockout. This  CFH –/– 
mouse, which demonstrated uncontrolled turnover of 
the alternative pathway with very low C3 levels, devel-
oped MPGN, not aHUS. A spontaneously arising  CFH -
deficient strain of pig has also been shown to develop 
MPGN, not aHUS.
 In order to better mimic the situation seen in aHUS, 
Pickering et al.  [11]  generated a transgenic mouse on the 
background of the  CFH –/– mouse which lacked the 5
C-terminal CCPs of  CFH ( CFH –/–  16–20). It is this re-
gion, shown to be important for cell-surface binding  [12] , 
which contains 80% of the factor H mutations reported 
to cause human aHUS.
 This  CFH –/–  16–20 mouse, which had higher plasma 
C3 levels compared to the  CFH –/– mouse, developed 
aHUS, not MPGN. Thus, this mouse model provides the 
first in vivo evidence that the  CFH mutations seen in 
aHUS impair endothelial cell surface recognition, result-
ing in local complement dysregulation, while controlling 
the alternative pathway in plasma (reviewed in Pickering 
et al.  [13] ). In these mice only the homozygous transgenic 
mice developed HUS, whereas in humans a heterozygous 
mutation is sufficient to predispose to aHUS. This may 
reflect the differences in complement regulation between 
the mouse and the human. Alternatively, it may mimic the 
human situation in which individuals are predisposed to 
aHUS by a  CFH mutation, but require an additional trig-
ger of complement activation (e.g. infection, drugs) for 
disease to manifest. Further investigation of the heterozy-
gote mouse response to such stimuli will be instructive.
 De Jorge et al. [ 14 ] have also crossed the  CFH –/–  16–
20  with  a  C5-deficient  mouse  to investigate the role of 
C5 activation in the pathogenesis of aHUS. These  C5 –/– 
 CFH –/–  16–20 mice, did not develop aHUS, suggesting a 
critical role downstream of C3b generation in aHUS and 
providing a rationale for use of C5 inhibition (e.g. eculizu-
mab) in the treatment of aHUS.
 Heterozygous mutations in complement factor I have 
also been shown to predispose to aHUS. The factor I 
knockout mouse ( CFI –/– ) shows uncontrolled alternative 
pathway activation; however, they do not develop aHUS, 
the pathological picture is of mesangial C3 deposits with 
nodular expansion.
 Although mutations in membrane cofactor protein 
(CD46;  MCP ) are associated with aHUS, the differences 
between human and murine complement systems pre-
clude an adequate mouse model. While CD46 is highly 
expressed on most human tissues including glomerular 
endothelium, in rodents CD46 is limited to the testes. In 
place of CD46, rodents express the rodent-specific com-
plement regulatory protein, Crry. Crry has decay-accel-
erating and co-factor activity. Although embryonically 
lethal, the  Crry knockout mouse ( Crry –/– ) can be rescued 
on a C3-deficient mouse ( Crry –/– C3 –/– ). When kidneys 
from  Crry –/– C3 –/– mice are transplanted into mice with a 
functioning complement system, the kidneys fail due to 
uncontrolled complement activation, principally in the 
tubulointerstitium. Although not the pathological pic-
ture of HUS, this confirms the necessity of Crry in the 
mouse kidney and highlights the differences between hu-
man and murine complement systems.
 ADAMTS13 Knockout Models of TTP 
 Thrombotic thrombocytopenic purpura has recently 
been shown to be a disorder of von Willebrand Factor 
(vWF) regulation  [3] . In response to vascular injury, 
stored vWF is released from endothelial cells as ultra 
large multimers (UL-vWF). However, some UL-vWF re-
main associated with the endothelial surface, providing 
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binding sites for platelets and possibly other blood com-
ponents such as leukocytes. The presence of UL-vWF 
may lead to spontaneous platelet aggregation in the cir-
culation or on the endothelial cell surface if it is not rap-
idly processed by the metalloprotease ADAMTS13. The 
discovery of ADAMTS13 as crucial to the pathogenesis of 
TTP led to two groups generating knockout mice in an 
attempt to produce an animal model of TTP resembling 
the rare human Upshaw-Schulman syndrome.
 Motto et al. [15] produced an ADAMTS13 knockout 
in two strains of mice. On the initial background (mixed 
genetic background C57BL/6 and 129 ! 1/Sv), which was 
subsequently shown to express a truncated form of 
 ADAMTS 13, there was complete loss of ADAMTS13 ac-
tivity. vWF-mediated interactions between platelets and 
vascular endothelium were prolonged compared to wild 
type. Despite this, there was no evidence of a thrombot-
ic microangiopathy and no difference in survival com-
pared to wild type. When this ADAMTS13 –/– mouse was 
crossed onto the genetically distant CASA/Rk mice 
(which express full length ADAMTS13), a number of the 
mice developed spontaneous thrombocytopenia with 
increased mortality. These mice had the vWF-rich and 
fibrin-poor hyaline thrombi characteristic of TTP in the 
small vessels of multiple organs, including the kidney. 
When these susceptible CASA/Rk ADAMTS13 –/– mice 
were exposed to IV Stx, most developed a picture con-
sistent with TTP that was not seen in the CASA/Rk 
 ADAMTS13 +/+ mice.
 As the CASA/Rk mice have higher plasma vWF levels 
than the mixed genetic background mouse, it had been 
proposed that this accounted for the difference in pheno-
type between these two models. However, early genera-
tions of the cross between these two mice produced a ran-
dom inheritance of vWF-regulatory factors leading to a 
heterogeneous population of knockouts with a wide range 
of vWF levels. In these mice, no correlation was seen be-
tween plasma vWF and the degree of Stx-induced throm-
bocytopenia or mortality. This suggests that the non-sus-
ceptible strain may contain other genetic differences that 
may protect against TMA.
 Banno et al.  [16] subsequently produced an AD-
AMTS13 knockout on pure strain 129/Sv mice, but these 
mice failed to show any evidence of thrombotic microan-
giopathy. The ADAMTS13 –/– mice did, however, show a 
UL-VWF multimer pattern, similar to that seen in TTP, 
compared to the ADAMTS13 +/+ which demonstrated a 
normal multimer pattern. When these ADAMTS13 –/– 
mice were challenged with the platelet and endothelial 
agonists, collagen and epinephrine, they developed a se-
vere thrombocytopenia compared to controls. However, 
mortality between the two groups was no different.
 Thus, these mice suggest that, in addition to AD-
AMTS13 deficiency, additional environmental and ge-
netic triggers are required for TTP to manifest.
 In addition to the ADAMTS13 knockout mice models 
of familial TTP, the ADAMTS 13 +/+ (on the non-TTP sus-
ceptible mouse strain) was injected with polyclonal rabbit 
antihuman ADAMTS13 antiserum in an effort to repli-
cate acquired TTP. These mice demonstrated significant-
ly prolonged vWF-mediated platelet-endothelial interac-
tions, similar to the untreated ADAMTS13 –/– mice not 
receiving antiserum  [17] , but did not develop TTP.
 VEGF Models of TMA 
 Vascular endothelial growth factor (VEGF) is one of 
the most important endothelial cell growth factors. In 
addition to its role in induction and maintenance of nor-
mal vascular endothelium it is markedly upregulated in 
many human tumours. Bevacizumab is a humanised 
monoclonal antibody against VEGF which, as part of 
chemotherapy regimens, improves survival rates by pre-
venting angiogenesis. A rare complication of this therapy 
has been the development of renal TMA. In the kidney, 
VEGF is constitutively expressed in the glomerular podo-
cytes. To examine the role of VEGF in TMAs, various 
mouse models of VEGF-A deficiency have been created.
 VEGF-A –/– and VEGF-A –/+ mice are embryonic lethal 
due to major vascular defects. To examine the role of 
VEGF in the kidney, a podocyte-specific deletion of 
VEGF was generated in mice. Podocyte-specific homo-
zygotes died perinatally with kidney failure and grossly 
abnormal glomeruli which lacked mature endothelial 
cells. Mice with podocyte-specific heterozygosity for 
VEGF developed endotheliosis and bloodless glomeruli, 
the renal lesion seen in pre-eclampsia, which progressed 
to nephrotic syndrome and then renal failure. In con-
trast, overexpression of the 164 isoform of VEGF-A in 
podocytes led to a collapsing glomerulopathy, which is 
the renal lesion seen in HIV-associated nephropathy  [18] . 
Thus, VEGF is critical for the normal development of the 
glomerulus.
 To test the role of VEGF inhibition in mature kidney, 
Eremina et al.  [19] used conditional gene targeting to de-
lete VEGF from the renal podocytes in adult mice. These 
mice developed typical features of thrombotic microan-
giopathy with intracapillary thrombi on electron micros-
copy mirroring the thrombotic microangiopathy seen in 
patients treated with bevacizumab. This suggests a pro-
tective role of VEGF in maintaining glomerular vascular 
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integrity and preventing the endothelial cell damage 
which may result in TMA.
 Renal Thrombotic Microangiopathy in a Genetic 
Hypertension Mouse Model 
 Malignant hypertension in humans can result in 
TMA. Transgenic mice that are hypertensive because of 
overexpression of the human renin (R + mice) and angio-
tensin (A + mice) genes develop renal thrombotic micro-
angiopathy when placed on a high salt diet and/or nitric 
oxide synthase inhibitor,  L -NAME, is added to drinking 
water. This model may lead to renal TMA by (a) hyper-
tensive endothelial cell injury, (b) inhibition of nitric ox-
ide synthase or (c) direct effect of high salt on renal blood 
vessels.
 What Are the Dangers of Extrapolation from Mice 
Models of TMA to Humans? 
 The simple transfer of knowledge from mice to hu-
mans is highly illusive. Because there are so many simi-
larities, there is a tendency to ignore differences and make 
the assumption that what is true in mice is true in hu-
mans. The genomes of mice and humans diverged ap-
proximately 65–75 million years ago. Mice and humans 
differ significantly in terms of size, lifespan and immu-
nological systems  [20] . For example, of potential signifi-
cance to the pathophysiology of TMAs are differences in 
the balance of leukocyte subsets, chemokine and cyto-
kine receptor expression, inducible nitric oxide synthase 
and complement regulatory proteins. Additionally, mice 
are housed in pathogen-free areas, and do not usually 
have other comorbid conditions. Mice are frequently in-
bred and the phenotype obtained can be dependent on 
the strain used, as in the ADAMTS13 –/– mouse models. 
One concern regarding the use of knockout mice is that 
the development of the immune system, in the absence of 
a specific protein, may result in the generation of con-
founding and unanticipated compensatory mechanisms. 
The use of transgenic mice may to some extent address 
these issues. This seems to be supported by the evidence 
from the podocyte conditional knockout of VEGF and 
the CFH –/–  16–20 mouse, which closely replicated the 
human conditions they attempted to model. Finally, de-
spite the hope that animal models will allow rapid iden-
tification of treatments for TMAs, there are many exam-
ples in the literature where therapeutic strategies devel-
oped in mouse models have not translated into successful 
human trials, e.g. blockade of TNF  for treatment of sep-
sis.
 Conclusions 
 Using the wide range of genetic and environmental 
triggers of TMAs a large number of animal models have 
been developed. The initial small animal models of Stx-
HUS were a poor imitation of the human disease while 
the large animal models are impractical for most labora-
tories to use. However, the recent introduction of geneti-
cally modified mice have probed specific pathways known 
to be perturbed in humans and this has provided better 
models of human disease. These mice may serve as a use-
ful platform for testing novel therapeutic strategies in 
these important conditions.
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